Printed as of 4/26/2024

Disclosures

Personal Commercial (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------|---------------------------|--------------------|---------------|
| Self | | | |
| 89bio | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Amarin | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |

Additional Personal Commercial Disclosures for Education Activities (0)

Novo Nordisk Inc.

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) | |
|---|------------------------------------|--------------------------|---------------|--|
| Self | | | | |
| VA Merit Award Research/Research Grants | | Significant (>= \$5,000) | Prevention | |
| Clinical Trial Enroller (3) | | | | |
| Trial Name | Trial Sponsor Trial Funding Source | | | |
| PROMINENT | Kowa | Kowa | | |
| HORIZON | Novartis Corporation | Novartis Corporation | | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|------|-------------|---------------------------|--|--------------------------|
| Self | | | | |
| 2020 | Lipitor MDL | Defendant † Pfizer Inc | Class Action Lawsuit alleging that Lipitor caused diabetes in women. | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

SELECT

Certified Education Attestation | Signed on 7/25/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement (Continuous) and the property of the propert

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/25/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/25/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/25/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

| involved in College governance, including disclosure statements. Compliance with | ding all committees and task forces, th this process is mandatory for part | programmatic, certified educationa icipation in College activities. | l, chapter, and other activities must p | provide complete, timely, accurate, and signed |
|--|--|---|---|--|
| alouiou o catoliiono. Compilano m | and proceed to managery for pair | ioipadon in conogo douvidos. | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |